激肽释放酶原(PK)重组蛋白

Recombinant Prekallikrein (PK)

KLKB1; KLK3; Fletcher Factor; Kallikrein B,Plasma; Kininogenin; Plasma prekallikrein

  • 激肽释放酶原(PK)重组蛋白产品包装(模拟)
  • 激肽释放酶原(PK)重组蛋白产品包装(模拟)
  • RPB801Hu01.jpgSDS-PAGE图
  • Certificate通过ISO 9001、ISO 13485质量体系认证

序列

用法

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

储存

避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。

相关产品

编号适用物种:Homo sapiens (Human,人)应用(仅供研究使用,不用于临床诊断!)
RPB801Hu01激肽释放酶原(PK)重组蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAB801Hu01激肽释放酶原(PK)多克隆抗体WB; IHC; ICC; IP.
MAB801Hu22激肽释放酶原(PK)单克隆抗体WB; IHC; ICC; IP.
SEB801Hu激肽释放酶原(PK)检测试剂盒(酶联免疫吸附试验法)Enzyme-linked immunosorbent assay for Antigen Detection.
LMB801Hu激肽释放酶原(PK)等多因子检测试剂盒(流式荧光发光法)FLIA Kit for Antigen Detection.

参考文献

杂志参考文献
Int J Immunopathol PharmacolAltered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes[PubMed: 25964383]
Thromb ResFactor XII–mediated contact activation related to poor prognosis in disseminated intravascular coagulation[PubMed: 26706311]
Thrombosis ResearchFactor XII-mediated contact activation related to poor prognosis in disseminated intravascular coaCavia (Guinea pig )lation[Pubmed:26706311]
Annals of Laboratory MedicineThe First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c. 1198G> T)[Pubmed: 30430790]
J Cell Mol MedHuaier shows anti©\cancer activities by inhibition of cell growth, migration and energy metabolism in lung cancer through PI3K/AKT/HIF©\1¦Á pathway[33377619]
J Thromb ThrombolysisContact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors[Pubmed:34993714]